Cubist Systematic Strategies LLC Has $731,000 Stock Holdings in Silence Therapeutics plc (NASDAQ:SLN)

Cubist Systematic Strategies LLC increased its holdings in shares of Silence Therapeutics plc (NASDAQ:SLN) by 129.6% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 106,320 shares of the company’s stock after purchasing an additional 60,015 shares during the period. Cubist Systematic Strategies LLC owned approximately 0.36% of Silence Therapeutics worth $731,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in the business. JPMorgan Chase & Co. acquired a new position in Silence Therapeutics in the 4th quarter valued at approximately $26,000. Barclays PLC raised its holdings in Silence Therapeutics by 83.8% in the 4th quarter. Barclays PLC now owns 6,126 shares of the company’s stock valued at $42,000 after acquiring an additional 2,793 shares in the last quarter. China Universal Asset Management Co. Ltd. acquired a new position in Silence Therapeutics in the 4th quarter valued at approximately $69,000. Virtus ETF Advisers LLC raised its holdings in Silence Therapeutics by 130.5% in the 4th quarter. Virtus ETF Advisers LLC now owns 10,772 shares of the company’s stock valued at $74,000 after acquiring an additional 6,098 shares in the last quarter. Finally, Ameriprise Financial Inc. acquired a new position in Silence Therapeutics in the 4th quarter valued at approximately $113,000. Institutional investors and hedge funds own 98.73% of the company’s stock.

Silence Therapeutics Price Performance

Shares of NASDAQ SLN opened at $4.06 on Thursday. The stock has a market capitalization of $121.52 million, a price-to-earnings ratio of -2.59 and a beta of 1.20. The business has a 50-day moving average of $3.34 and a 200-day moving average of $6.28. Silence Therapeutics plc has a fifty-two week low of $1.97 and a fifty-two week high of $24.38.

Silence Therapeutics (NASDAQ:SLN) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.60) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.42). The business had revenue of $0.14 million for the quarter, compared to the consensus estimate of $3.58 million. Silence Therapeutics had a negative return on equity of 62.81% and a negative net margin of 342.00%. On average, sell-side analysts expect that Silence Therapeutics plc will post -1.77 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the company. Chardan Capital cut their price target on Silence Therapeutics from $55.00 to $35.00 and set a “buy” rating for the company in a report on Friday, May 9th. Morgan Stanley cut their price target on Silence Therapeutics from $45.00 to $25.00 and set an “overweight” rating for the company in a report on Friday, May 9th. The Goldman Sachs Group cut their price target on Silence Therapeutics from $4.00 to $3.00 and set a “sell” rating for the company in a report on Friday, May 9th. BMO Capital Markets cut their price target on Silence Therapeutics from $67.00 to $25.00 and set an “outperform” rating for the company in a report on Tuesday, March 4th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $75.00 price target on shares of Silence Therapeutics in a report on Friday, March 7th. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. According to MarketBeat, Silence Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $33.83.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.